These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33250741)

  • 41. Molecular Monitoring of Chronic Myeloid Leukemia.
    Dominy K; Mokretar K; Reid AG; Khorashad JS
    Methods Mol Biol; 2020; 2065():153-173. PubMed ID: 31578694
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?
    Colafigli G; Scalzulli E; Di Prima A; Pepe S; Loglisci MG; Diverio D; Martelli M; Foà R; Breccia M
    Crit Rev Oncol Hematol; 2021 Jan; 157():103163. PubMed ID: 33246263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission.
    van Kooten Niekerk PB; Petersen CC; Nyvold CG; Ommen HB; Roug AS; Nederby L; Hokland P; Kjeldsen E
    Br J Haematol; 2014 Jan; 164(1):53-60. PubMed ID: 24903628
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation.
    Kottwitz D; El Hadi H; El Amrani M; Cabezas S; Dehbi H; Nadifi S; Quessar A; Colomer D; Moumen A; Sefrioui EL
    Int J Hematol; 2015 Sep; 102(3):335-41. PubMed ID: 26243622
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia.
    Greiner G; Ratzinger F; Gurbisz M; Witzeneder N; Taghizadeh H; Mustafa SGK; Mitterbauer-Hohendanner G; Esterbauer H; Mannhalter C; Sperr WR; Valent P; Hoermann G
    Clin Chem Lab Med; 2020 Jul; 58(8):1214-1222. PubMed ID: 32084002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Quantitative BCR-ABL1 RQ-PCR fusion transcript monitoring in chronic myelogenous leukemia.
    Moore FR; Rempfer CB; Press RD
    Methods Mol Biol; 2013; 999():1-23. PubMed ID: 23666687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.
    Song HY; Noh H; Choi SY; Lee SE; Kim SH; Kee KM; Yoo HL; Lee MY; Kang KH; Suh JH; Yang SY; Jang EJ; Lee JI; Kim DW
    Cancer Med; 2018 Oct; 7(10):5107-5117. PubMed ID: 30171671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response.
    Mohd Yacob A; Muhamad NA; Chang KM; Akmal Hisham H; Mat Yusoff Y; Ibrahim L
    BMC Cancer; 2022 Mar; 22(1):332. PubMed ID: 35346116
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular monitoring in CML and the prospects for treatment-free remissions.
    Deininger MW
    Hematology Am Soc Hematol Educ Program; 2015; 2015():257-63. PubMed ID: 26637731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.
    Serpa M; Sanabani SS; Dorliac-Llacer PE; Conchon M; Pereira TD; Nardinelli L; Costa JL; Novaes MM; Ferreira Pde B; Bendit I
    BMC Blood Disord; 2010 Nov; 10():7. PubMed ID: 21087500
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.
    Malagola M; Iurlo A; Abruzzese E; Bonifacio M; Stagno F; Binotto G; D'Adda M; Lunghi M; Crugnola M; Ferrari ML; Lunghi F; Castagnetti F; Rosti G; Lemoli RM; Sancetta R; Coppi MR; Corsetti MT; Rege Cambrin G; Romano A; Tiribelli M; Russo Rossi A; Russo S; Aprile L; Bocchia M; Gandolfi L; Farina M; Bernardi S; Polverelli N; Roccaro AM; De Vivo A; Baccarani M; Russo D
    Cancer Med; 2021 Mar; 10(5):1726-1737. PubMed ID: 33594821
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Arpinati M; Tolomelli G; Bochicchio MT; Castagnetti F; Amabile M; Bandini G; Bonifazi F; Stanzani M; Rosti G; Martinelli G; Baccarani M
    Biol Blood Marrow Transplant; 2013 May; 19(5):735-40. PubMed ID: 23333776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response.
    Iacobucci I; Lonetti A; Venturi C; Ferrari A; Papayannidis C; Ottaviani E; Abbenante MC; Paolini S; Bresciani P; Potenza L; Parisi S; Cattina F; Soverini S; Russo D; Luppi M; Martinelli G
    Leuk Res; 2014 May; 38(5):581-5. PubMed ID: 24630366
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Digital PCR for Minimal Residual Disease Quantitation Using Immunoglobulin/T-Cell Receptor Gene Rearrangements in Acute Lymphoblastic Leukemia: A Proposed Analytic Algorithm.
    Lu Y; Li Z; Lim EH; Huan PT; Kham SKY; Yeoh AE
    J Mol Diagn; 2022 Jun; 24(6):655-665. PubMed ID: 35390515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR].
    Moravcová J; Brdicka R
    Cas Lek Cesk; 2005; 144(1):32-7. PubMed ID: 15789779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alignment of Qx100/Qx200 Droplet Digital (Bio-Rad) and QuantStudio 3D (Thermofisher) Digital PCR for Quantification of BCR-ABL1 in Ph+ Chronic Myeloid Leukemia.
    Fava C; Bernardi S; Gottardi EM; Lorenzatti R; Galeotti L; Ceccherini F; Cordoni F; Daraio F; Giugliano E; Jovanovski A; Petiti J; Varotto M; Barberio D; Rege-Cambrin G; Berchialla P; Sciannameo V; Malagola M; Saglio G; Russo D
    Diseases; 2021 May; 9(2):. PubMed ID: 34062996
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.